These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19156505)

  • 1. A new probabilistic rule for drug-dug interaction prediction.
    Zhou J; Qin Z; Quinney SK; Kim S; Wang Z; Yu M; Chien JY; Lucksiri A; Hall SD; Li L
    J Pharmacokinet Pharmacodyn; 2009 Feb; 36(1):1-18. PubMed ID: 19156505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bayesian meta-analysis on published sample mean and variance pharmacokinetic data with application to drug-drug interaction prediction.
    Yu M; Kim S; Wang Z; Hall S; Li L
    J Biopharm Stat; 2008; 18(6):1063-83. PubMed ID: 18991108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-drug interaction prediction: a Bayesian meta-analysis approach.
    Li L; Yu M; Chin R; Lucksiri A; Flockhart DA; Hall SD
    Stat Med; 2007 Sep; 26(20):3700-21. PubMed ID: 17357990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-drug interaction prediction assessment.
    Zhou J; Qin Z; Sara QK; Kim S; Wang Z; Hall SD; Li L
    J Biopharm Stat; 2009 Jul; 19(4):641-57. PubMed ID: 20183431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.
    Perdaems N; Blasco H; Vinson C; Chenel M; Whalley S; Cazade F; Bouzom F
    Clin Pharmacokinet; 2010 Apr; 49(4):239-58. PubMed ID: 20214408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models.
    Yamada M; Ishizuka T; Inoue SI; Rozehnal V; Fischer T; Sugiyama D
    Drug Metab Dispos; 2020 Sep; 48(9):769-777. PubMed ID: 32616542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
    Prakash C; Fan B; Ke A; Le K; Yang H
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting the Drug-Drug Interaction Mediated by CYP3A4 Inhibition: Method Development and Performance Evaluation.
    Ren HC; Sai Y; Chen T; Zhang C; Tang L; Yang CG
    AAPS J; 2021 Dec; 24(1):12. PubMed ID: 34893925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability considerations in evaluating drug-drug interactions using the population pharmacokinetic approach.
    Duan JZ; Jackson AJ; Zhao P
    J Clin Pharmacol; 2011 Jul; 51(7):1087-100. PubMed ID: 20864622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
    Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
    Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
    Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J
    Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.
    Chien JY; Lucksiri A; Ernest CS; Gorski JC; Wrighton SA; Hall SD
    Drug Metab Dispos; 2006 Jul; 34(7):1208-19. PubMed ID: 16611859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of nonlinear midazolam pharmacokinetics on the magnitude of the midazolam-ketoconazole interaction in rats.
    Vuppugalla R; Zhang Y; Chang S; Rodrigues AD; Marathe PH
    Xenobiotica; 2012 Nov; 42(11):1058-68. PubMed ID: 22574883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically Based Pharmacokinetic Modeling of Palbociclib.
    Yu Y; Loi CM; Hoffman J; Wang D
    J Clin Pharmacol; 2017 Feb; 57(2):173-184. PubMed ID: 27402157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm.
    Stoch SA; Friedman E; Maes A; Yee K; Xu Y; Larson P; Fitzgerald M; Chodakewitz J; Wagner JA
    J Clin Pharmacol; 2009 Apr; 49(4):398-406. PubMed ID: 19246722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.
    Greenblatt DJ; Harmatz JS
    Br J Clin Pharmacol; 2015 Sep; 80(3):342-50. PubMed ID: 25923589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
    Walzer M; Bekersky I; Blum RA; Tolbert D
    Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults.
    Yang J; Nikanjam M; Capparelli EV; Tsunoda SM; Greenberg HE; Penzak SR; Stoch SA; Bertino JS; Nafziger AN; Ma JD
    J Clin Pharmacol; 2019 Nov; 59(11):1495-1504. PubMed ID: 31051051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
    Ono C; Hsyu PH; Abbas R; Loi CM; Yamazaki S
    Drug Metab Dispos; 2017 Apr; 45(4):390-398. PubMed ID: 28167538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of the Impact of Cytochrome P450 2C9 Genotypes on the Drug-Drug Interaction Potential of Siponimod With Physiologically-Based Pharmacokinetic Modeling: A Comprehensive Approach for Drug Label Recommendations.
    Huth F; Gardin A; Umehara K; He H
    Clin Pharmacol Ther; 2019 Nov; 106(5):1113-1124. PubMed ID: 31199498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.